Clinical Trial Update: Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating a triple combination of empagliflozin, linagliptin, and metformin to improve glycemic control in type 2 diabetes; currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)
• Linagliptin (linagliptin)
• metformin (metformin)

Snippet

Sponsor: Nabiqasim Industries (Pvt) Ltd | Conditions: Diabetes Mellitus, Type 2 DM | Phase 4 | Status: RECRUITING